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bursement for new health technologies are largely based on effective-
ness estimates. Sometimes, however, the target effectiveness
estimates are not readily available. This may be because many
alternative instruments measuring these outcomes are being used
(and not all always reported) or an extended follow-up time of clinical
trials is needed to evaluate long-term end points, leading to the
limited data on the target clinical outcome. In the areas of highest
priority in health care, decisions are required to be made on a short
time scale. Therefore, alternative clinical outcomes, including surro-
gate end points, are increasingly being considered for use in evidence
synthesis as part of economic evaluation. Objective: To illustrate the
potential effect of reduced uncertainty around the clinical outcome on
the utility when estimating it from a multivariate meta-analysis.
Methods: Bayesian multivariate meta-analysis has been used to
synthesize data on correlated outcomes in rheumatoid arthritis and
to incorporate external data in the model in the form of informative
prior distributions. Estimates of Health Assessment Questionnaire2014, International Society for Pharmacoeconomic
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Open access under CC BY license.were then mapped onto the health-related quality-of-life measure
EuroQol ﬁve-dimensional questionnaire, and the effect was compared
with mapping the Health Assessment Questionnaire obtained from the
univariate approach. Results: The use of multivariate meta-analysis
can lead to reduced uncertainty around the effectiveness parameter and
ultimately uncertainty around the utility. Conclusions: By allowing all
the relevant data to be incorporated in estimating clinical effectiveness
outcomes, multivariate meta-analysis can improve the estimation of
health utilities estimated through mapping methods. While reduced
uncertainty may have an effect on decisions based on economic
evaluation of new health technologies, the use of short-term surrogate
end points can allow for early decisions. More research is needed to
determine the circumstances under which uncertainty is reduced.
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In health technology assessment (HTA), decisions are made about
reimbursement of new health technologies. Such decisions are
largely based on effectiveness outcomes, alongside cost and
quality-of-life estimates. Effectiveness measures are usually esti-
mated by meta-analyzing outcomes from randomized controlled
trials (RCTs). The outcomes of interest (target outcomes), how-
ever, are sometimes not readily available. It may prove too costly
to obtain the target clinical end point, or take an extended period
of time to measure these outcomes, both of which conﬂict with
the need for efﬁcient and timely assessment of new technologies,
especially in areas of health care that are considered a priority insociety, such as cancer. Another reason for the target outcome
not always being readily available is the wide diversity of
alternative instruments measuring disease activity or response
to treatment, as is the case, for example, in rheumatoid arthritis
(RA), leading to a variation in the choice of an end point for a
primary outcome in RCTs. Taking into account only the target
outcome measure can lead to the amount of data included in the
meta-analysis being radically reduced. In circumstances of
absence of data on the target clinical outcome, surrogate end
points are sometimes used in lieu of that outcome [1]. Alter-
natively, in some circumstances, data on the target end point
may exist, but, in addition to this primary outcome, are also
available either on alternative scales or measured by a surrogates and Outcomes Research (ISPOR).
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primary outcome, for example, when such an end point can be
measured early, leading to a shorter time to licensing and hence
quicker proﬁt from the new pharmaceutical product. When a
drug is conditionally licensed on the basis of a biomarker, data
needed for HTA, such as overall survival in cancer treatments,
are not available from the clinical trial evaluating this product.
Multivariate approach to meta-analysis can allow us to include
the data on the biomarker by combining it with data on the
target outcome from other RCTs. Synthesizing the data from all
sources of evidence can lead to a reduced bias [2] and potentially
also the uncertainty [3].
Multivariate meta-analytic methods have already been devel-
oped to simultaneously synthesize evidence from correlated
outcomes [4,5]. In a recent review, Jackson et al. [6] describe
advances in the development of the methodology of multivariate
meta-analysis and discuss the advantages and disadvantages of
the use of these methods. Bujkiewicz et al. [3] have recently
developed a Bayesian multivariate meta-analysis (MVMA) frame-
work for combining data frommultiple correlated outcomes. One
of the advantages of the multivariate approach that was
exploited in this model was the incorporation of additional data
by the inclusion of studies reporting multiple outcomes. In
addition to this, the Bayesian aspect of this approach made it
possible to incorporate external data in the MVMA model in the
form of informative prior distributions, especially on correla-
tions. This method, developed using an example in RA for
combining data from studies reporting the Health Assessment
Questionnaire (HAQ) and the Disease Activity Score 28 (DAS-28)
measures, and the American College of Rheumatology (ACR)
response criteria, allowed for extending the range of data that
could be included in the analysis, thus reducing possible biases
[2] and also led to a reduced uncertainty around the outcome of
interest (the HAQ in this case). The aim of this work was to apply
such a multivariate meta-analytic framework that allows evi-
dence to be combined from studies that are a mixture of those
reporting the target clinical outcome, an alternative clinical end
point, or both (rather than reducing the number of studies to
those reporting the clinical outcome of interest or including the
surrogate end point alone in the economic model) to jointly
estimate the effect of treatment on the HAQ. This is a ﬂexible
approach that permits the use of multiple outcomes and hence
prevents valuable data from clinical trials from being discarded
and potentially can lead to reduced uncertainty around the
clinical outcome of interest.
Clinical effectiveness outcomes are often used to derive
health-related quality-of-life or utility estimates, as part of the
economic evaluation of the new health technologies. Increas-
ingly, mapping methods are being developed to predict health
state utility values from preference-based measures, such as
EuroQoL ﬁve-dimensional (EQ-5D) questionnaire values, using
disease-speciﬁc outcomes. For example, mapping methods have
been applied to predict EQ-5D questionnaire values from 1) the
St. George’s Respiratory Questionnaire in patients with chronic
obstructive pulmonary disease [7], 2) functional assessment of
cancer therapy-melanoma [8], 3) disease-speciﬁc quality-of-life
scores in patients with migraine [9], 4) the Western Ontario and
McMaster Universities Osteoarthritis Index in patients with
knee osteoarthritis [10], and, ﬁnally, 5) using the HAQ in RA
[11,12].
In this article, we explore how using the multivariate Baye-
sian evidence synthesis can lead to a better estimation of the
target clinical outcome in RA, in this case the HAQ. We then
explore how reduced uncertainty around the HAQ, obtained from
the MVMA, can ultimately lead to a better estimation of health
utility such as the EQ-5D questionnaire obtained by a mapping
technique.Methods
Sources of Evidence
As our motivating example, we used a systematic review and
meta-analysis that was carried out by Lloyd et al. [13] to inves-
tigate the effectiveness of the TNF-α inhibitors—etanercept,
inﬂiximab, and adalimumab—used sequentially (as a second-
line treatment in patients who switched from one anti-TNF to
another because of lack of response or adverse effects on the ﬁrst)
in the treatment of RA. The data from this systematic review are
single arm (i.e., uncontrolled) because of the lack of comparative
studies such as RCTs evaluating these treatments as second-line
treatment. Outcome measures included in the analysis in this
article were among the standard instruments used for measuring
response to treatment in RA: changes from baseline in the HAQ
(ΔHAQ) and DAS-28 (ΔDAS-28) measures, and 20% response to
treatment measured by the ACR criteria (ACR-20). Data collected
in this systematic review were used to investigate how the
MVMA can be applied to simultaneously incorporate multiple
outcomes of effectiveness in evidence synthesis. Table 1 gives
details of the three outcomes that were reported in each of the
studies within the systematic review. We will refer to these data
as the “Lloyd data” throughout this article.
Additional sources of evidence were used to construct prior
distributions for some of the parameters of the Bayesian evidence
synthesis model. External individual patient data (IPD) were
obtained from the British Rheumatoid Outcome Study Group
trial, which was designed to assess the beneﬁt of aggressive
disease-modifying anti–rheumatic drug treatments in patients
with established RA [14]. The trial, which recruited 466 patients
with stable RA, assessed clinical outcomes (i.e., HAQ, DAS-28, and
ACR-20) in two cohorts of patients managed by using either a
regime focused on symptomatic control of pain and stiffness in
the shared care setting or a more aggressive regime focusing on
control of symptoms and joint inﬂammation in the hospital
setting. (The British Rheumatoid Outcome Study Group trial
found no difference between the aggressive and symptomatic
treatment arms; therefore, this data set was used as a single
cohort of 466 patients with established RA.) Another source of
evidence, external summary data (ESD), was obtained from a
systematic review of the anti–TNF-α inhibitors in biologically
naive patients [15]. Both external sources of evidence (IPD and
ESD) were used to construct prior distributions for correlations
between outcomes as described below.
Evidence Synthesis: Statistical Methods
In our motivating example, we aimed to model the summary
data of the correlated outcomes from the Lloyd data by using an
MVMA in a Bayesian form. We used a trivariate random-effects
meta-analysis (TRMA), described in much more detail elsewhere
[3], in the following form:
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which has a hierarchical structure: the correlated outcomes
(ΔHAQ, ΔDAS, and ACR-20) in each study i follow a multivariate
normal distribution and they are assumed to be the estimates of
Table 1 – Studies and outcomes included in the “Lloyd data.”
Study Mean (SE) ACR-20 r/n
ΔHAQ ΔDAS-28
Bennett (2005) [34] 0.31 (0.13) 1.7 (0.25) –
Bingham (2009) [35] 0.35 (0.05) 1.6 (0.1) 85/188
Bombardieri (2007) [36] 0.48 (0.02) 1.9 (0.05) 486/810
Haraoui (2004) [37] 0.45 (0.14) – 14/22
Hyrich (2008) [38] 0.12 (0.03) – –
Iannone (2007) [39] 0.15 (0.13) – –
Navarro-Sarabia (2009) [40] 0.21 (0.07) 1.1 (0.18) –
Van der Bijl (2008) [41] 0.21 (0.08) 1.5 (0.25) 19/41
Buch (2007) [42] – 1.47 (0.18) 55/72
Cohen (2005) [43] – 1.87 (0.24) –
Di Poi (2007) [44] – 2.1 (0.29) –
Finckh (2007) [45] – 0.98 (0.18) –
Hjardem (2007) [46] – 1 (0.11) –
Laas (2008) InTol [47] – 1.17 (0.66) –
Laas (2008) InEff [47] – 1.26 (0.35) –
Nikas (2006) [48] – 2.4 (0.16) 18/24
Wick (2005) EA [49] – 1.9 (0.22) 7/9
Wick (2005) IA [49] – 1.3 (0.28) 19/27
Buch (2005) [50] – – 18/25
Karlsson (2008) [51] – – 172/337
van Vollenhoven (2003) [52] – – 12/18
ACR-20, 20% response to treatment measured by the American College of Rheumatology criteria; DAS-28, Disease Activity Score 28; EA,
switchers from Etanercept to Adalimumab; HAQ, Health Assessment Questionnaire; IA, switchers from Inﬂiximab to Adalimumab; InEff,
switchers for reason of inefﬁcacy; InTol, switchers for reason of intolerance; SE, standard error.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 0 9 – 1 1 5 111underlying correlated effects (μHi, μDi, μAi) for the individual
studies (the within-study models in Equation 1). These study-
level effects are assumed to follow a common distribution (the
between-study model in Equation 2). This meta-analytic model
can be used for bivariate and univariate analyses by reducing the
size of the matrices in the equations. The within-study variances
(s2Hi,s
2
Di,s
2
Ai) are assumed to be known (for studies reporting the
relevant outcomes), but prior distributions need to be speciﬁed
for the within-study correlations ðρHDwi , ρHAwi , ρDAwi Þ because none of
the studies in the Lloyd data reported them. Prior distributions
for the within-study correlations were constructed by using the
external IPD described earlier. The elements of the covariance
matrix of the between-study model—the between-study varian-
ces (τ2H,τ
2
D,τ
2
A) and the between-study correlations (ρ
HD
b , ρ
HA
b , ρ
DA
b )—
also need prior distributions to be placed on them. In our model,
prior distributions on the between-study correlations were con-
structed by meta-analyzing ESD by using the trivariate model (see
Equations 1 and 2), but this time with noninformative prior
distributions. Resulting posterior between-study correlations
were then used as prior distributions to the between-study
correlations in meta-analysis of the Lloyd data. To inform the
between-study correlation by the ESD directly, the between-study
model was parameterized in the form of the product of univariate
conditional distributions (in contrast to using a multivariate
Normal distribution, as in Equation 2, and a prior distribution on
the precision matrix). Noninformative (half-normal) prior distri-
butions are placed on the standard deviations (SDs) of these
conditional distributions. ΔDAS-28 and ACR-20 are both condi-
tional on ΔHAQ in this model. This parameterization assumes a
conditional independence between ΔDAS-28 and ACR-20 that is
equivalent to setting the partial correlation between ΔDAS-28 and
ACR-20 to zero (but not the implied correlation; for details, see the
Appendix in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2013.11.005). This assumption may sometimes be too
strong, for example, in the circumstances in which the twovariables are strongly correlated and then the implied correlation
between them may be underestimated. This should not, however,
have an effect on the estimation of the target outcome (ΔHAQ in
this case). We have carried out a sensitivity analysis on the ESD to
investigate the effect of the choice of the parameterization on
estimates and in particular the resulting prior distributions for the
between-study correlations, by using the spherical decomposition
of the between-study covariance matrix [16,17]. Details of this
sensitivity analysis are included in the Appendix in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.11.005. The
advantages of this approach along with all the details of the
statistical modeling (including models in different number of
outcomes) are reported elsewhere [3]. This evidence synthesis
aimed to give an estimate of ΔHAQ from all available sources of
evidence of the effectiveness (of studies reporting various out-
comes), which can then be used to estimate the change from
baseline in the EQ-5D questionnaire score, ΔEQ-5D.
Mapping the HAQ Onto the EQ-5D Questionnaire
A number of methodological approaches to modeling utility
estimates in RA for the purpose of economic evaluation have
been developed. The estimate of the HAQ, a self-reported meas-
ure of physical function, is often used to predict EQ-5D ques-
tionnaire scores, an estimate of health-related quality of life, by
mapping the HAQ score onto EQ-5D questionnaire scores [11,12].
These methods often focus on the relationship between EQ-5D
questionnaire scores and HAQ scores, usually expressed in a
linear form [11], and have been compared with EQ-5D values
based on patient responses in a number of data sets in RA [12]. In
a systematic review, Lloyd et al. [13] found that very few studies
reported the HAQ score, but there were other instruments used to
assess patients’ response to treatment (ACR response criteria and
the DAS-28 measure). The relevant instruments are summarized
in Table 2. Using the multivariate evidence synthesis framework
Table 2 – Relevant instruments measuring disease activity and/or response to treatment in patients with RA.
Measure Description Range (best to
worst)
Form used in this
article
Disease Activity Score
(DAS-28)
Composite of disease activity based on 28 swollen
and tender joint count, ESR (or CRP), and
patient global assessment [19]
0–9.3 Change from baseline
(ΔDAS-28)
American College of
Rheumatology (ACR)
criteria
Indicated by % improvement in tender or swollen
joint counts and three of the following ﬁve
measures: acute-phase reactant (e.g., ESR/CRP),
patient global assessment, physician global
assessment, pain scale (e.g., pain VAS),
disability/function (e.g., the HAQ) [20]
1, 0 (binary outcome) 20% improvement
(ACR-20)
Health Assessment
Questionnaire (HAQ)
Functional disability assessed on eight domains
(dressing and grooming, rising, eating, walking,
hygiene, reach, grip, activities) [21]
0–3 Change from baseline
(ΔHAQ)
ACR-20, 20% response to treatment measured by the ACR criteria; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RA,
rheumatoid arthritis; VAS, visual analogue scale.
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other measures of response to treatment in estimating the HAQ.
The purpose of this article was to illustrate the potential effect of
reduced uncertainty around the clinical outcome on the utility
when estimating it from an MVMA. To do this, we modeled the
relationship between the HAQ and the health-related quality-of-
life measure, the EQ-5D questionnaire, in a linear form estimated
by Chen et al. [15] from data reported in a study by Hurst et al.
[18]: EQ-5D ¼ a þ b  HAQ, where the intercept a  Nðμa,s2aÞ and
slope b  Nðμb,s2bÞ, with means μa ¼ 0.628 and μb ¼ 0.327 and SDs
sa ¼ 0.034 and sb ¼ 0.021, respectively (note that this approach
assumed independence of intercept and slope). This relationship
can be assumed to remain the same at any time point; hence, the
relationship between the change from baseline in the EQ-5D
questionnaire score and the change from baseline in the HAQ
estimate can be modeled as ΔEQ-5D ¼ b  ΔHAQ.
The change from baseline in the HAQ estimate, ΔHAQ, used in
the above mapping equation, typically comes from a meta-
analysis. As can be seen in Table 1, there are only eight studies
reporting the HAQ in the Lloyd data, while there were many more
studies investigating the effectiveness of the same treatment in
the same type of patients but reporting DAS-28 and/or ACR-20.
To be able to include all outcome data from all studies, we
have used the multivariate approach to meta-analysis as
described above.Table 3 – Results of evidence synthesis from the three m
related quality-of-life estimates.
Model Number of
cohorts/
studies
ΔHAQ
HAQ only 8/8 0.25 (0.43, 0.09)
DAS-28 only 15/13 – 1.
ACR-20 only 11/10 –
HAQ and DAS-28 18/16 0.28 (0.41, 0.14) 1.
HAQ and ACR-20 15/14 0.31 (0.5, 0.13)
DAS and ACR-20 19 – 1.
HAQ, DAS-28,
and ACR-20
21/19 0.28 (0.42, 0.13) 1.
ACR-20, 20% response to treatment measured by the American Colleg
analysis; DAS-28, Disease Activity Score 28; EQ-5D, EuroQol ﬁve-dime
random-effects meta-analysis; URMA, univariate random-effects meta-aSoftware Implementation
All models were implemented in WinBUGS [22] in which the
estimates were obtained by using Markov chain Monte Carlo
simulation using 100,000 iterations (including 50,000 burn-in). All
posterior estimates are presented as means, with measure of
uncertainty for each estimate represented by the 95% highest
probability density interval (HPDI) [23] obtained by using the BOA
package [24].Results
We have applied the MVMA model to the Lloyd data to model
simultaneously data on the HAQ, DAS-28, and ACR-20. To inves-
tigate the effect of including more data in the analysis on
uncertainty around the HAQ estimate and consequently the EQ-
5D questionnaire score, we explored results of the meta-analyses
on three levels: using univariate random-effects meta-analysis
(URMA) of ΔHAQ, bivariate random-effects meta-analysis (BRMA)
combining ΔHAQ and ΔDAS-28, and ﬁnally TRMA by extending
the data by including ACR-20. The prior correlations between
DAS-28 and the HAQ obtained from the external data were as
follows: ρHDwi ¼ 0.24 (95% HPDI 0.13–0.35) obtained from the IPD and
ρHDb ¼ 0.86 (95% HPDI 0.46–0.999) obtained from bivariate meta-
analysis of the ESD. For the trivariate case, the prior within-studyodels: URMA, BRMA, and TRMA and resulting health-
ΔDAS-28 ACR-20 ΔEQ-5D
 – 0.083 (0.025, 0.142)
57 (1.84, 1.31) – –
– 62% (53%, 71%) –
51 (1.67, 1.35) – 0.091 (0.044, 0.139)
– 60% (51%, 69%) 0.101 (0.039, 0.163)
56 (1.82, 1.30) 62% (52%, 71%) –
51 (1.70, 1.33) 61% (52%, 71%) 0.091 (0.041, 0.142)
e of Rheumatology criteria; BRMA, bivariate random-effects meta-
nsional; HAQ, Health Assessment Questionnaire; TRMA, trivariate
nalysis.
Fig 1 – Estimates of change from baseline of HAQ, obtained frommeta-analysis of HAQ only, HAQ and DAS-28 and ﬁnally HAQ,
DAS-28 and ACR20, and resulting estimates of the change from baseline in EQ-5D.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 0 9 – 1 1 5 113correlations, constructed by using the IPD, were ρHDwi ¼ 0.24
(95% HPDI 0.10–0.38), ρHAwi ¼ 0.13 (95% HPDI 0.29 to 0.0103),
and ρDAwi ¼ 0.20 (95% HPDI 0.31 to 0.08), and the prior between-
study correlations, constructed by using the ESD, were ρHDb ¼ 0.78
(95% HPDI 0.27–0.998) and ρHAb ¼ 0.14 (95% HPDI 0.80 to 0.56)
(only the two correlations were required in the product normal
parameterization of the between-study model).
Table 3 shows results of applying all the three models,
including all univariate and bivariate models for the complete-
ness of the results. Mapping estimate of ΔHAQ of 0.25 (95%
HPDI 0.43 to 0.09), obtained from URMA of the eight studies
reporting only HAQ outcomes, resulted in ΔEQ-5D equal to 0.08
(95% HPDI 0.025–0.141). Extending the evidence synthesis by 10
cohorts reporting ΔDAS-28 (but not ΔHAQ), by the use of BRMA,
led to a shift in the estimate of the HAQ and the reduction in the
uncertainty around the estimate to 0.28 (95% HPDI 0.41 to
0.14). This has also reduced the uncertainty around the esti-
mate of ΔEQ-5D, which in this case was 0.09 (95% HPDI 0.041–
0.138). This effect can be seen in Figure 1 in which horizontal
lines represent 95% HPDIs. The intervals are reduced for the
estimates of ΔHAQ and ΔEQ-5D when using BRMA compared
with URMA. As can be seen in Table 3 and also in Figure 1,
extending the evidence synthesis to TRMA by adding further
three studies reporting ACR-20 did not contribute to a further
reduction in the uncertainty around the estimates of interest
(ΔHAQ and ΔEQ-5D). This is likely due to increased heterogeneity
by introducing the three studies. More detailed description of
results (related to the effectiveness outcomes only) are reported
elsewhere [3]. Results of the bivariate meta-analyses of the HAQ
with ACR-20 and of DAS-28 with ACR-20 are shown in Table 3 for
completeness. Bivariate model of the HAQ and ACR-20 did not
lead to reduced uncertainty around the HAQ similarly as for the
trivariate case discussed above.Discussion
We have applied a Bayesian meta-analytic framework to synthe-
size diverse sources of evidence and multiple end points in RA.
Our aim was to increase the use of available data to estimate the
effectiveness of second-line biologics used in the treatment of
RA, measured by the change from baseline in the HAQ score and
ultimately the health-related quality of life measured by the
change from baseline in the EQ-5D questionnaire score. We used
external IPD to construct prior distributions for within-study
correlations and ESD for between-study correlations. We found
that using this Bayesian approach to evidence synthesis of
outcomes in RA, by combining the HAQ end point with DAS-28,
leads to a 20% reduction in the uncertainty around the HAQ from
0.25 (95% HPDI 0.43 to 0.09) obtained from URMA of synthe-
sizing data on the HAQ alone to 0.28 (95% HPDI 0.41 to 0.14)
obtained from BRMA. The use of BRMA has also led to a
reduced uncertainty, by 16%, around the health-related quality-
of-life estimate, the EQ-5D questionnaire, from 0.083 (95% HPDI0.025–0.141) when mapping the HAQ obtained from URMA to
0.091 (95% HPDI 0.044–0.139) when using the estimate of the
HAQ from BRMA. Similar results have been obtained when using
TRMA of the HAQ, DAS-28, and ACR-20. The inclusion of the third
outcome, ACR-20, did not contribute to the HAQ estimate or
further reduction of uncertainty around it. A 20% reduction in
uncertainty around the effectiveness outcome may lead to a
change in the cost-effectiveness outcomes, for example, alter the
cost-effectiveness acceptability curve, leading to a change in a
decision made on the basis of such analysis. Joint analysis of
multiple outcomes may have advantages in many areas of
decision making, for example, in risk-beneﬁt analysis, in which
multiple outcomes contribute to net beneﬁt function and some-
times the risk function as well. For example, in a study on
hormone replacement therapy by Minelli et al. [25], net beneﬁt
was constructed by adding the beneﬁts measure by relative risk
of hip fracture, menopausal symptoms, colorectal cancer, and
endometrial cancer, whereas the overall harm was estimated by
combining the relative risk of breast cancer, coronary heart
disease, pulmonary embolism, and stroke. Each of these eight
outcomes was estimated by a separate univariate meta-analysis.
Modeling such outcomes jointly may lead to more precise
estimates especially in circumstances in which outcomes are
measured in RCTs that are powered with respect to one outcome
but may be underpowered for others. This may also be the case
when adverse events are included in the analysis while RCTs are
not powered for such outcomes; therefore, there is a lot of
uncertainty about them when including them in net beneﬁt
analysis.
When pooling data by means of the Bayesian random-effects
meta-analysis, we allow for “borrowing of strength” across
studies, which leads to “shrinkage” of the estimates from indi-
vidual studies toward the overall mean (with reduced uncertainty
around the estimates) [23]. In addition to this, an MVMA allows
borrowing of strength across outcomes. This may lead to reduced
uncertainty around the pooled estimates. It is difﬁcult, however,
to predict the extent of the gain in precision of the estimates. In
fact, the inclusion of studies reporting additional outcomes
through the multivariate approach can lead to higher hetero-
geneity in the data set (which is the case in our example in RA
when extending the bivariate case by the third outcome), which
can in fact lead to increased uncertainty. The issue of the
potential gain in precision of the estimates obtained from multi-
variate models has been discussed previously. Nam et al. [4]
observed that the gain is more likely to be noticeable when the
data sets are small. Riley et al. [5] showed that the gain in
precision is expected unless either the outcomes are not corre-
lated or the data are complete on both outcomes, which are also
reported with equal variance. In their recent review, Jackson et al.
[6] reported that the gain in precision increases with increased
within-study correlation, but noted that it can also depend on the
between-study variance. While the factors driving the uncer-
tainty around the estimates of the multivariate meta-analytic
models seem complex and it is difﬁcult to predict the gain in
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 0 9 – 1 1 5114precision or whether its degree will be satisfactory to analysts,
there are further advantages of using the multivariate scheme.
Restricting the analysis to a single outcome may lead to ignoring
data from clinical trials that either report treatment effect
measured by a different instrument(s) or simply choose to report
only positive and/or signiﬁcant results. In the former case, the
multivariate approach allows using more diverse sources of
evidence and hence prevents relevant data from being discarded.
In the latter case, in the presence of outcome reporting bias, the
multivariate approach can lead to a more appropriate estimate of
the clinical outcome as has been shown by Kirkham et al. [2]. This
may apply to the case of RA in which, due to the availability of a
number of instruments for measuring the disease activity or
response to treatment, authors may choose to report only those
outcomes whose estimates are positive and/or signiﬁcant. The
pooling of multiple outcomes through the multivariate approach
can obviously be achieved by means of frequentist analysis. The
Bayesian approach, however, brings additional advantages of
incorporating external evidence in the form of prior distributions.
Individual patient data (used in our example to construct prior
distributions for within-study correlations) are not always avail-
able. Other sources of evidence, however, can be used to inform
the parameters of the model. The Bayesian approach, for exam-
ple, allows elicitation techniques to be used to take into account
experts’ opinions in the form of prior distributions in a model. For
example, methods for inclusion of expert opinion on bias in the
synthesis of studies were developed by Turner et al. [26].
Implementing such Bayesian analysis requires the use of special-
ist software such as WinBUGS, which can be viewed as a
limitation by analysts. MVMA can also be conducted, for exam-
ple, in Stata by using the mvmeta command [27] or in R mvmeta
package [28] in a frequentist approach. WinBUGS, however,
provides a suitable software environment for implementing a
full Bayesian framework with the use of external evidence and
can be interfaced with R, which is convenient when decision
models are developed in R [29].
In this multivariate approach to evidence synthesis, studies
reporting various relevant measures associated with an outcome
of interest can be included. Outcomes can include surrogate end
points, so far mostly used instead of the primary outcome of
interest when there is no available evidence on the target outcome
[1]. In the method described here, the surrogate outcomes are used
alongside the primary outcome, and therefore the analysis is not
restricted to a single primary outcome or a surrogate end point.
The main interest of this research is in uncertainty (and magni-
tude of the effect) in terms of the HAQ and also the EQ-5D
questionnaire because it is this outcome that is used for decision
making. In our example, none of the studies in the Lloyd data
reported the EQ-5D questionnaire and hence the linear mapping
was chosen to estimate the EQ-5D questionnaire from the HAQ.
When some of the studies included in evidence synthesis report
the EQ-5D questionnaire, however, the MVMA can include the EQ-
5D questionnaire as one of the multiple outcomes and the pooled
effect is then estimated simultaneously with the clinical outcomes
(borrowing strength from data across studies and outcomes).
Clinical outcomes can then be considered surrogate end points
to utility. This approach may be preferable to linear mapping
because regression models are often developed on the basis of a
small amount of data. Cooper et al. [30] have shown that the data
quality (together with quantity, and therefore uncertainty) can be
least for utility estimates (e.g., the EQ-5D questionnaire), especially
compared with effectiveness, and, therefore, in the absence of
better direct utility data, the methods considered here may at least
reduce uncertainty in the decision problem.
In our view, the approach described here is an important step
toward the inclusion of surrogate end points in HTA, especially in
the early stages of the drug development process when the targetoutcome is not readily available. Modeling simultaneously data
on surrogate (potentially short-term outcome) and the ultimate
end point can increase the available evidence, allowing analysts
and decision makers an early assessment of new technologies.
Surrogate end points play an increasingly important role in drug
development as reported by the European Medicines Agency [31]
and HTA, and their use will need to increase in HTA as
reimbursement decisions are taken closer to regulatory ones
[32] and RCTs become shorter in duration [33].
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